Results
The total number of fetal records during 2011–2014 within the JECS was
104,102. A total of 86,370 participants met the inclusion criteria
(Figure 1). Among them, 5,354 participants had uterine myomas (myoma
group), while the remaining 81,016 were the participants without uterine
myomas (control group).
Table 1 summarizes clinical and demographic characteristics, and
obstetric outcomes. Except for II, the incidence of APOs was higher in
the myoma group than in the control group.
The aORs of PTB before 37, and 34 weeks, pPROM, II, and GH in the myoma
group were 1.37 (95% confidence interval [CI], 1.22–1.54), 1.61
(95% CI, 1.27–2.05), 1.65 (95% CI, 1.33–2.04), 1.05 (95% CI,
0.75–1.46), and 1.20 (95% CI, 1.05–1.38), respectively. The aORs of
PTB, pPROM, and GH were significantly higher in the myoma group than
that in control group (Table 2).
The aORs of PTB and pPROM in women with II and uterine myomas were 1.81
(95% CI, 0.64–5.15) and 1.29 (95% CI, 0.17–9.54), while the aORs of
PTB and pPROM in women with II without uterine myomas were 3.16 (95%
CI, 2.39–4.19) and 5.54 (95% CI, 3.72–8.25), respectively. Although
the aORs of PTB and pPROM were significantly increased in women with II
without uterine myomas, the aORs were not significantly increased in
women with II and uterine myomas (Table 3).